Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
2024年6月24日 - 9:30PM
Creative Medical Technology Holdings, Inc. (“Creative Medical
Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial
stage biotechnology company focused on a regenerative approach to
immunotherapy, urology, neurology, and orthopedics, today announced
that it has successfully generated human induced pluripotent stem
cells (iPSC)-derived Islet Cells that produce human insulin.
The iPSC clinical line that generated these
insulin producing Islet Cells is part of the Company’s iPSCelz®
program, which is validated by Greenstone Biosciences Inc.
(“Greenstone”). The iPSC clinical line, which is currently utilized
in a number of our FDA cleared clinical programs in the U.S., has
also been utilized to derive validated mesenchymal cells and
T-regulatory cells.
Timothy Warbington, President and CEO of the
Company, commented, “The production of human insulin from islets
derived from the IPSCelz® program is a significant milestone for
the Creative Medical Team and a reflection of the leadership role
we have assumed in developing these therapies. It was only year ago
that we confirmed the development of our iPSC. As we said then, we
estimated that the development of this cell line would save the
Company two to three years in research and development time along
with associated expenses. Today, we are thrilled to be able to
announce the evolution of this program with the creation of insulin
producing Islet Cells derived from our iPSC. We believe that this
development has the potential for not only clinical translation of
the human Islet Cells, but also the stand-alone human insulin which
is produced by these cells. We are currently in strategic
discussions on “next step” collaborations to further these
programs.”
“The Company continues to achieve significant
milestones with its multiple programs in a cost-efficient manner
without sacrificing quality and maintaining strict adherence to all
regulatory requirements,” Mr. Warbington continued. “We are focused
on allocating our resources in a prudent and effective manner which
we believe is evidenced by our achievements and a slower burn rate
than many companies in our space.”
About IPSCelz®iPSCelz®, which
is protected by trade secrets and published U.S. patents, utilizes
the companies xeno-free human perinatal cell line derived from
qualified human donors which are then converted into IPS
cells. These cells are incubated with the Company’s cell-free
reprogramming “cocktail” to create the human islets and other cell
types.
About Creative Medical Technology
HoldingsCreative Medical Technology Holdings, Inc. is a
commercial stage biotechnology company specializing in stem cell
technology in the fields of immunotherapy, urology, neurology, and
orthopedics. For further information about the Company, please
visit www.creativemedicaltechnology.com.
Forward Looking StatementsThis
news release may contain forward-looking statements including but
not limited to comments regarding the timing and content of
upcoming clinical trials and laboratory results, marketing efforts,
funding, etc. Forward-looking statements address future events and
conditions and, therefore, involve inherent risks and
uncertainties. Actual results may differ materially from those
currently anticipated in such statements. See the periodic and
other reports filed by Creative Medical Technology Holdings, Inc.
with the Securities and Exchange Commission and available on the
Commission's website at www.sec.gov.
Company Contact |
Investor Relations |
Creative Medical Technology |
Devin Sullivan, Managing Director |
IR@CreativeMedicalTechnology.com |
The Equity Group Inc. |
|
dsullivan@equityny.com |
|
|
|
Conor Rodriguez, Analyst |
|
crodriguez@equityny.com |
Creative Medical Technol... (NASDAQ:CELZ)
過去 株価チャート
から 8 2024 まで 9 2024
Creative Medical Technol... (NASDAQ:CELZ)
過去 株価チャート
から 9 2023 まで 9 2024